We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
55 result(s) found, displaying 11 to 20
-
Designation or determinationProvisional approval
-
Designation or determinationOrphan drug
-
Prescription medicine registrationActive ingredients: avelumab.
-
Cancellation by sponsorRequested by Merck Healthcare Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PERGOVERIS follitropin alfa (rch) /lutropin alfa (rch) 900 IU/450 IU in 1.44 mL solution for injection cartridge pre-assembled in a pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PERGOVERIS follitropin alfa (rch) /lutropin alfa (rch) 450 IU/225 IU in 0.72 mL solution for injection cartridge pre-assembled in a pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PERGOVERIS follitropin alfa (rch) /lutropin alfa (rch) 300 IU/150 IU in 0.48 mL solution for injection cartridge pre-assembled in a pen.
-
Designation or determinationOrphan drug
-
Cancellation by sponsorRequested by Merck Healthcare Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BAVENCIO avelumab (rch) 200 mg/10 mL concentrated solution for intravenous infusion vial.